Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Aug 10;30(37):5496-9.
doi: 10.1016/j.vaccine.2012.06.057. Epub 2012 Jun 28.

Reduction of HPV infections through vaccination among at-risk urban adolescents

Affiliations

Reduction of HPV infections through vaccination among at-risk urban adolescents

Teresa Cummings et al. Vaccine. .

Abstract

Introduction: Human papillomavirus (HPV) vaccine trials have demonstrated high efficacy in preventing HPV infections and HPV related disease in females ages 16-26. However, there is no source data to demonstrate the impact of the vaccine in other populations who may be at higher risk for HPV related disease. This study examines the impact of HPV vaccination on subsequent HPV detection and sexual behaviors among urban adolescents in a clinical setting.

Methods: A cohort of adolescent women, ages 14-17, were recruited prospectively and matched to historical controls to assess the impact of HPV vaccination. All women completed the same questionnaire and face-to-face interview that assessed sexual behaviors; all provided a clinician or self-collected vaginal swab that was used to test for sexually transmitted infections, including HPV. Logistic regression models, incorporating random pair effects, were used to assess the impact of the HPV vaccine on HPV detection and sexual behaviors between the two groups.

Results: Each woman recruited (N=75) was matched to 2 historical controls (HC); most of the recruited women (89.3%) had received one or more doses of the HPV vaccine. At enrollment, detection of quadrivalent vaccine types (HPV 6, 11, 16 and 18) was significantly less in the recruited group (5.3%) as compared to the HC (24%): OR=5.6 (CI=1.9, 16.5), p=0.002. Adolescent women in the HC had a 9.5 times greater odds of HPV infection when the analysis was adjusted to compare those who had 2 or more vaccine doses to their matched controls. The only behavioral difference found was that the recruited women used condoms more frequently.

Conclusion: This study demonstrates that HPV vaccination was associated with fewer vaccine-type HPV infections despite incomplete vaccination and high risk sexual behaviors. These data also suggest that sexual behaviors were not altered because of the vaccine.

PubMed Disclaimer

Conflict of interest statement

Disclosed potential conflicts of interest

GDZ: Investigator on research projects funded by Merck & Co.’s Investigator-Initiated Studies Program

DB: Serves on the Women’s Health Advisory Board at Merck and Co. and investigator on a research project funded by Merck’s Investigator-Initiated Studies Program. Through a confidential agreement between Merck and the University, receives a portion of income from related to vaccine development.

MLS: Clinical Investigator (Merck & Co.) for HPV related vaccine trials

Similar articles

Cited by

References

    1. Villa LL, Costa RLR, Petta CA, Andrade RP, Ault KA, Giuliano AR, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. The lancet oncology. 2005;6(5):271–278. - PubMed
    1. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007 May 10;356(19):1928–1943. - PubMed
    1. Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006 Apr 15;367(9518):1247–1255. - PubMed
    1. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, et al. A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine. 2002;347(21):1645–1651. - PubMed
    1. Gavin L, MacKay AP, Brown K, Harrier S, Ventura SJ, Kann L, et al. Sexual and reproductive health of persons aged 10–24 years - United States, 2002–2007. MMWR Surveill Summ. 2009 Jul 17;58(6):1–58. - PubMed

Publication types

MeSH terms

Substances